Open AccessGalectin‐3 as an Immunohistochemical Tool to Distinguish Pilocytic Astrocytomas from Diffuse Astrocytomas, and Glioblastomas from Anaplastic Oligodendrogliomas
Author(s) -
Neder Luciano,
Marie Suely K Nagahashi,
Carlotti Carlos Gilberto,
Gabbai Alberto Alain,
Rosemberg Sérgio,
Malheiros Suzana MF,
Siqueira Rodrigo Proto,
ObaShinjo Sueli Mieko,
Uno Miyuki,
Aguiar Paulo Henrique,
Miura Flavio,
Chammas Roger,
Colli Benedicto Oscar,
Silva Wilson Araujo,
Zago Marco A.
Publication year - 2004
Publication title -
brain pathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.986
H-Index - 132
eISSN - 1750-3639
pISSN - 1015-6305
DOI - 10.1111/j.1750-3639.2004.tb00083.x
Subject(s) - immunohistochemistry , anaplastic astrocytoma , pathology , astrocytoma , pilocytic astrocytoma , oligodendroglioma , glioma , medicine , cancer research
The distinction of astrocytomas and oligodendrogliomas, mainly pilocytic astrocytomas (PILOs) from infiltrating astrocytomas and oligodendrogliomas (ODs), and high‐grade oligodendrogliomas from glioblastomas (GBMs), poses a serious clinical problem. There is no useful immunohistochemical (IHC) marker to differentiate these gliomas, and sometimes the differential diagnosis between them is arbitrary. We identified galectin‐3 (Gal‐3) as a possible tool to differentiate them based on gene expression profiles of GBMs. We confirmed the differential expression in 45 surgical samples (thirteen GBMs; seven PILOs; 5 grade II ODs; 5 anaplastic oligodendrogliomas [AODs], including 2 Oligo‐astrocytomas; 8 diffuse astrocytomas [ASTs], and 7 non‐neoplastic samples) by quantification of Gal‐3 gene expression by real‐time quantitative PCR (rt‐PCR). Higher expression of Gal‐3 was observed in GBMs and PILOs than in OD, AODs and ASTs. The IHC expression of Gal‐3 was evaluated in 90 specimens (fifteen PILOs, fourteen ASTs, 10 anaplastic astrocytomas, fifteen GBMs, eleven ODs, fifteen AODs, and 10 dysembryoplastic neuroepithelial tumors). The mean labeling score for Gal‐3 determined according to the percentage of labeled cells in the tumor bulk was significantly different in GBMs versus AODs and in PILOs versus ASTs. Hence, Gal‐3 is differentially expressed in central nervous system tumors, making IHC detection of Gal‐3 a useful tool in distinguishing between these gliomas.